Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective
Clinical Pharmacology & Therapeutics2015Vol. 97(3), pp. 247–262
Citations Over TimeTop 1% of 2015 papers
HM Jones, Yuan Chen, Christopher R. Gibson, Tycho Heimbach, Neil Parrott, SA Peters, Jan Snoeys, Vijay Upreti, Ming Zheng, S D Hall
Abstract
The application of physiologically based pharmacokinetic (PBPK) modeling has developed rapidly within the pharmaceutical industry and is becoming an integral part of drug discovery and development. In this study, we provide a cross pharmaceutical industry position on "how PBPK modeling can be applied in industry" focusing on the strategies for application of PBPK at different stages, an associated perspective on the confidence and challenges, as well as guidance on interacting with regulatory agencies and internal best practices.
Related Papers
- → Whole body physiologically-based pharmacokinetic models: their use in clinical drug development(2008)152 cited
- → Whole-animal cellular and molecular imaging to accelerate drug development(2002)97 cited
- → Human Pluripotent Stem-Cell-Derived Models as a Missing Link in Drug Discovery and Development(2021)16 cited
- → University—industry collaboration in the pharmaceutical sciences(1996)3 cited
- Strategic responses by manufacturing pharmaceutical firms to changes in the pharmaceutical industry in Kenya(2011)